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Appendix 1. Acronyms or abbreviations for studies included in the current report 
and their key references linked to the Web references 
 
1. General population cohorts 
Aichi:   Aichi Workers’ Cohort1 
AKDN (Dip):  Alberta Kidney Disease Network2 
ARIC:   Atherosclerosis Risk in Communities Study3 
AusDiab:   Australian Diabetes, Obesity, and Lifestyle Study4 
Beaver Dam:   Beaver Dam CKD Study5 
Beijing:   Beijing Cohort Study6 
CHS:    Cardiovascular Health Study7 
CIRCS:  Circulatory Risk in Communities Study8 
COBRA:   COBRA Study9 
ESTHER:   ESTHER Study10 
Framingham:  Framingham Heart Study11 
Gubbio:   Gubbio Study12 
HUNT:   Nord Trøndelag Health Study13 
IPHS:    Ibaraki Prefectural Health Study14 
MESA:   Multi-Ethnic Study of Atherosclerosis15 
MRC Older People: MRC Study of assessment of older people16 
NHANES III:  Third US National Health and Nutrition Examination Survey17 
Ohasama:   Ohasama Study18 
Okinawa83:  Okinawa 83 Cohort19 
Okinawa93:  Okinawa 93 Cohort20 
PREVEND:   Prevention of Renal and Vascular End-stage Disease Study21 
Rancho Bernardo:  Rancho Bernardo Study22 
REGARDS:   Reasons for Geographic And Racial Differences in Stroke Study23 
Severance:   Severance Cohort Study24   
Taiwan:   Taiwan MJ Cohort Study25 
ULSAM:   Uppsala Longitudinal Study of Adult Men26 
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2. High-risk cohorts 
ADVANCE:  The Action in Diabetes and Vascular Disease: Preterax and Diamicron 
Modified Release Controlled Evaluation (ADVANCE) trial27 
AKDN (ACR): Alberta Kidney Disease Network2 
CARE:   The Cholesterol and Recurrent Events (CARE) Trial28 
KEEP:   Kidney Early Evaluation Program29 
KP Hawaii:   Kaiser Permanente Hawaii Cohort30 
MRFIT:   Multiple Risk Factor Intervention Trial31 
Pima:    Pima Indian Study32 
ZODIAC:   Zwolle Outpatient Diabetes project Integrating Available Care33 
 
3. CKD cohorts 
AASK:   African American Study of Kidney Disease and Hypertension34 
BC CKD  British Columbia CKD Study35 
CRIB:    Chronic Renal Impairment in Birmingham36 
Geisinger:  Geisinger CKD Study37 
GLOMMS-1: GLOMMS-1: Grampian Laboratory Outcomes, Morbidity and Mortality 
Studies – 138 
KPNW:  Kaiser Permanente Northwest39 
MASTERPLAN:  Multifactorial Approach and Superior Treatment Efficacy in Renal 
Patients with the Aid of a Nurse Practitioner40 
MDRD:   Modification of Diet in Renal Disease Study41 
MMKD:   Mild to Moderate Kidney Disease Study42 
Nephro Test:  NephroTest Study43 
RENAAL:   Reduction of Endpoints in Non-insulin Dependent Diabetes Mellitus with 
the Angiotensin II Antagonist Losartan44 
Steno:    Steno Type 1 Diabetes Study45 
Sunnybrook:  Sunnybrook Cohort46 
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Appendix 2. Data analysis overview and analytic notes for some of individual studies 
 
Overview: 
As previously reported,47 48 participating studies were asked to prepare a dataset with 
approximately 30 variables (follow-up time, event variable, and several predictors including age, 
gender, race, and serum creatinine to estimate GFR and albuminuria). Because the analysis used 
the CKD-EPI formula, the race variable only distinguished between black and non-black, under 
the assumption that this formula performs reasonably well in other ethnic groups. To minimize 
heterogeneity, we circulated guidelines for definitions of variables (e.g. hypertension, diabetes, 
smoking) and dataset preparation. Analyses were restricted to subjects aged 18 years or older. 
We instructed studies not to impute the two key kidney measures, eGFR (i.e., age, gender, race, 
and serum creatinine) and albuminuria. Values of eGFR >200 were treated as 200. Zero values 
of ACR were treated as 0.1 for log transformation. For other variables in the models with 
missing values we imputed with the mean value of the covariate. Individuals with practically 
impossible values of covariates, i.e., systolic blood pressure <50 or >300 mmHg or BMI <10 
or >100 kg/m2 were excluded from the analysis (<0.01 %).  
 
For 35 of the 45 studies analysis was done at the Data Coordination Center at Johns Hopkins 
University; for the remainder the standard code was run in-house at individual study centers, 
with the output returned to the Data Coordinating Center. The code was written in STATA by 
the Data Coordinating Center. The standard code was designed to automatically save all output 
needed for the meta-analysis. The Data Coordinating Center then pooled the estimates across 
studies using STATA.   
 
Studies were instructed to standardize and calibrate their serum creatinine to their best ability and 
report the method of standardization.  The reported creatinine calibration allows grouping studies 
into studies that reported using an IDMS traceable method or conducted some serum creatinine 
calibration to IDMS traceable methods (AKDN, AusDiab, Beaver Dam, Geisinger, GLOMMS-1, 
Gubbio, HUNT, KEEP, KPNW, MMKD, NephroTest, NHANES III, Okinawa 83 and 93, 
Rancho Bernardo, REGARDS) and studies where the creatinine standardization was not done 
(AASK, ADVANCE, Aichi, ARIC, British Columbia CKD, Beijing, CARE, CHS, CIRCS, 
COBRA, CRIB, ESTHER, Framingham, IPHS, KP Hawaii, MASTERPLAN, MDRD, MESA, 
MRC Older People, MRFIT, Ohasama, Pima, PREVEND, RENAAL, Severance, STENO, 
Sunnybrook, Taiwan, ULSAM, ZODIAC).  Retrospective assessment of creatinine calibration 
without direct collection of laboratory data is limited since substantial creatinine calibration 
differences have been documented even within a single laboratory using the same method over 
time.  
 
The reference range of eGFR (90-104 ml/min/1.73 m2) was chosen based on the optimal level of 
GFR (≥90 ml/min/1.73 m2) reported in current clinical guidelines49 50 and the fact that some 
studies have reported higher mortality risk at high eGFR.51-53 The reference point of eGFR (95 
ml/min/1.73 m2) was then arbitrarily chosen within the reference range but not in the knots (90 
and 105) used to create splines.   
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Following the published results from individual studies, we assumed the proportional hazards 
model provided the best summary of the data in each study and did not summarize statistics on 
deviations from proportionality across the covariates.   
 
 
Notes for individual studies: 
 
1. General population cohorts 
 
Aichi: Blood pressure was measured by auscultation with an appropriate arm cuff and a mercury 
column manometer or an automatic sphygmomanometer after at least 5 minutes of rest.  
 
ARIC: Blood pressure was measured twice using a random-zero sphygmomanometer after 5 
minutes of rest. The average of the two measurements was recorded. 
 
AusDiab: Blood pressure measurement was performed in a seated position using a 
dinamap/mercury sphygmomanometer after participants had rested for at least 5 minutes. Three 
readings were taken at 1-minute intervals. The mean of the first two readings was recorded. If the 
difference between the three readings was greater than 10mmHg, the mean of the two closest 
measurements was used.  
 
AKDN: Although this study has not collected information on race, the proportion of blacks in the 
province of Alberta is considered <1%.2 Other variables that were not collected in this study are 
systolic blood pressure, total cholesterol concentration, and smoking. Hypertension is defined 
based on administrative data.   
 
Beaver Dam: Blood pressure was measured 3 times using a random zero mercury 
sphygmomanometer after 5 minutes of rest. The average of the last two measurements was 
reported.  
 
Beijing: Blood pressure was taken 3 times after resting for at least 30 min using a standard 
mercury sphygmomanometer. The mean of the first 2 readings was calculated, unless the 
difference between these readings was >10 mmHg, in which case the mean of the 2 closest of 3 
measurements was used. 
 
CHS: This study consists of participants only aged 65 or older and thus did not contribute to the 
subgroup analysis of younger population. Blood pressure was measured 3 times in the seated 
position with a random zero sphygmomanometer and the average was recorded. 
 
CIRCS: Blood pressure was measured using standard mercury sphygmomanometers on the right 
arm of seated participants after at least a 5-minute rest. When the first systolic blood pressure 
reading was ≥140 mmHg and/or diastolic blood pressure was ≥ 90 mmHg, the physicians 
repeated the measurement. For these cases, the second reading was used in the analyses, and 
otherwise the first reading was used. 
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COBRA: Current smokers in this study include chewable tobacco users. Blood pressure was then 
measured 3 times with a calibrated automated device in the sitting position after 5 minutes of rest. 
The average of the last two measurements was recorded. 
 
ESTHER: This study only measured urine albumin excretion with the minimum detection value 
of 11.3 mg/L (equivalent to ACR 17 mg/g) and thus its reference proteinuria group (≤11.3 mg/L) 
was likely to contain individuals with ACR ≥10 mg/g. Therefore, this study was meta-analyzed 
with the dipstick studies, translating urine albumin excretion (≤11.3, 11.4-19.9, 20-199 and ≥200 
mg/L to -, ±, +, and ≥++). Blood pressure measurement was taken in the physicians’ offices as 
routine part of the health check-up and documented accordingly on the respective questionnaire. 
It was explicitly stated in the questionnaire to repeat any measurements over 140/90mmHg. 
 
Framingham: Blood pressure was obtained twice in the left arm of seated subjects using a 
mercury column sphygmomanometer positioned near eye level. The average of two readings was 
used for each blood pressure variable. 
 
Gubbio: This study consists of participants aged between 45 and 64 and thus did not contribute 
to the subgroup analysis of older population. Blood pressure was measured 3 times 1 minute 
apart using a mercury column sphygmomanometer after a 5 minute rest. The averaged values of 
second and third readings were recorded. 
 
HUNT: This study is a general-population study overall but measured urine albumin mainly in 
participants with treated hypertension or diabetes. However, this study was categorized as a 
general population cohort, since they measured albuminuria in a 5% random sample out of 
≈65,000 participants and, thus, the relationship between kidney measures and risk was 
maintained. This study has not collected use of anti-diabetic medication and use of statins (and 
thus hypercholesterolemia). Most of the glucose measurements were non-fasting. Three 
consecutive standardized blood pressure measurements were recorded, with a 1-minute interval. 
Measurements were performed in the sitting position after a minimum of 2 minutes of rest using 
an automatic oscillometric method. The mean of the second and third measurements was 
recorded. 
 
IPHS: This study categorized their dipstick data - and ± into the same group. Therefore, dipstick 
data - and ± were treated as a reference group, and this study did not contribute to estimates of 
dipstick ±. Blood pressure was measured using a standard mercury sphygmomanometer on the 
right arm of seated participants who had rested for at least 5 minutes. When systolic BP was 
greater than 150 mm Hg or diastolic BP was greater than 90 mm Hg, BP was measured again 
after several deep breaths, and the lower BP values, which were almost always observed after the 
second measurement, were used for analyses. 
 
MESA: Blood pressure was measured 3 times in the seated position using an automated 
oscillometric sphygmomanometer after 5 minutes of rest. The average of the last two 
measurements was used in analysis. 
 
MRC Older People: This study categorized their dipstick data - and ± into the same group. 
Therefore, dipstick data - and ± were treated as a reference group, and this study did not 
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contribute to estimates of dipstick ±. This study has not collected total cholesterol. This study 
consists of participants aged ≥75 years old and thus did not contribute to the subgroup analysis of 
younger population. Blood pressure was measured 2 times using Hawkskey Random Zero 
Sphynomanometers. The average was recorded. 
 
NHANESIII: This study did not collect data on total cholesterol, hypercholesterolemia, or use of 
anti-diabetic medications. Blood pressure was measured 3 times using a mercury 
sphygmomanometer after 5 minutes of rest. The average of the second and third values was used. 
 
Ohasama: This study has not collected data on use of anti-diabetic medications. Blood pressure 
was measured 2 times using a semiautomatic devise after at least 2 minutes of rest. The average 
of these 2 readings was recorded. 
 
Okinawa 83: This study has not collected data on fasting glucose, smoking, history of 
cardiovascular disease, anti-diabetic or anti-hypertensive medications. Hypertension was defined 
using blood pressure (systolic ≥140 mmHg and diastolic ≥90 mmHg) measurements only. Blood 
pressure was measured with a standard mercury sphygmomanometer while the person being 
screened is in the sitting position. 
 
Okinawa 93: This study has not collected data on fasting glucose, smoking, history of 
cardiovascular disease, anti-diabetic or anti-hypertensive medications. Hypertension was defined 
using blood pressure (systolic ≥140 mmHg and diastolic ≥90 mmHg) measurements only. Blood 
pressure was measured with a standard mercury sphygmomanometer while the person being 
screened is in the sitting position. 
 
PREVEND: At baseline, PREVEND study participants had two visits to the study outpatient 
clinic within ~3 weeks. Blood pressure was measured at both visits in supine position, every 
minute, for 10 and 8 min, respectively, with an automatic Dinamap XL Model 9300 series device 
(Johnson and Johnson, Medical Inc., Arlington, TX). Systolic and diastolic BP was calculated as 
the mean of the last two measurements of the two visits. 
 
Rancho Bernardo: Systolic and diastolic blood pressures were measured twice using a mercury 
sphygmomanometer in seated subjects after a 5 minute rest. 
 
REGARDS: Blood pressure was measured 2 times using a standard aneroid sphygmomanometer. 
 
Severance: Blood pressure was measured 2 times using a standard electronic 
sphygmomanometer after a 5 minutes rest. The average of two consecutive measurements with a 
5 minute interval was used for analysis. 
 
Taiwan: Blood pressure in the right arm was measured twice at 10 minute intervals, with the 
participants seated after a 5 minute rest, using a computerized auto-mercury sphygmomanometer. 
The mean of the 2 measurements was used for the analysis. 
 
ULSAM: This study measured urinary albumin excretion rate (µg/min), which was converted to 
mg/day by multiplying 1.44. All participants aged 65 or older and thus this study did not 
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contribute to the subgroup analysis of younger population. This study consists of only men. 
Blood pressure was measured 2 times in the right arm after a 10 minute rest. The mean of the 
two values was used in analyses. 
 
 
2. High-risk cohorts 
 
ADVANCE: This study is an intervention study which includes participants with diabetes only. 
Blood pressure was measured 2 times using a standardised automated sphygmomanometer after 
5 minutes of rest. The mean of the two measurements was recorded. 
 
CARE: This study is an intervention study in which all patients had a previous myocardial 
infarction. This study did not include dipstick category “+++”. Due to many missing values, data 
for fasting glucose and BMI were not included.  
 
KEEP: Blood pressure was measured 2 times using either an oscillometric device (digital or 
electronic) or aneroid devices (manual inflatable cuff with stethoscope) after 5 minutes of rest. 
The average of the two measurements was recorded. 
 
KP Hawaii: In this study for participants with only ACR, PCR was imputed by ACR * 1.5. This 
study did not collect data on fasting glucose, hypertension status, hypercholesterolemia status, 
diastolic blood pressure, anti-diabetic or anti-hypertensive medications. Hypertension was 
defined using systolic blood pressure (≥140 mmHg) measurements only. Outpatient blood 
pressure values recorded in the electronic medical record. 
 
MRFIT: This study is an intervention study which includes men at above risk (study specified) 
for coronary heart disease based on higher levels of blood pressure, serum cholesterol, and 
cigarette use.  Men were excluded if their serum creatinine was > 2.0 mg/dl.  The study only 
included men. Blood pressure was measured 3 times using a standard nonzero mercury 
sphygmomanometer. The mean of the second and third diastolic blood pressures was used. 
 
Pima: This study consists entirely of Pima and the closely-related Tohono O’odham Indians. 
ACR was measured in a spot urine specimen. History of cardiovascular disease was not recorded 
in this study. Blood pressure was measured 2 times using a mercury sphygmomanometer after 5 
minutes of rest. The two measures were averaged. 
 
ZODIAC: This study includes only individuals with type 2 diabetes. This study has not collected 
data on fasting glucose or hypercholesterolemia. Blood pressure was measured 2 times with a 
Welch Allyn Sphygmomanometer in the supine position after at least 5 min of rest. The mean 
blood pressure of two recordings was calculated. 
 
3. CKD cohorts 
 
AASK: This study is an intervention study which includes African American participants only. 
All participants were free of diabetes. Blood pressure was measured 3 times using a Hawksley 
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random zero sphygmomanometer after 5 minutes of rest. The mean of the last two readings was 
recorded. 
 
CRIB: Blood pressure was recorded on two occasions 5 minutes apart with the subject in the 
sitting position and the arm rested on a table, using an automated oscillometric device. Mean 
systolic, diastolic, and pulse pressures were calculated. 
 
Geisinger: This study includes all Geisinger primary care recipients, 18 years or older as of index 
date, and who have CKD, defined as two or more outpatient eGFR values < 60 by CKD-EPI 
equation. Covariates obtained most closely to index date within a past year were included in 
models. The measurement of blood pressure in all Geisinger Clinics is performed with 
sphygmomanometers from a single manufacturer. Individual clinics order whichever model they 
choose. During the study time frame, the majority of clinics were using aneroid 
sphygmomanometers. However, measurements were also taken using mercury 
sphygmomanometers. 
 
GLOMMS-1: This study did not collect data on use of anti-diabetic or anti-hypertensive 
medication, total cholesterol, systolic or diastolic blood pressure, or BMI. Diabetes and 
hypertension status were coded based on hospital physician or general practitioner diagnosis 
recorded in case notes. The ethnicity of the Grampian population is relatively homogenous with 
overall 98.3% of males and 98.4% of females being white. Indians account for 0.2% of the 
population, Pakastani and other South Asian individuals account for 0.3%, Chinese 0.3% and 
0.8% are recorded as other.54 
 
KPNW: This study defined diabetes using their own clinical tool that includes diagnosis codes, 
treatment codes, and laboratory values. This study has not collected use of anti-diabetic 
medications. Outpatient blood pressure values recorded in the electronic medical record. 
 
MASTERPLAN: This study measured ACR in patients with albuminuria in the low range, PCR 
in patients with overt proteinuria. Thus, for those participants with only ACR, PCR was imputed 
by ACR * 1.5. Blood pressure was measured 5 times using an oscillometric device after 15 
minutes of rest. The mean of the five measures was recorded. 
 
MDRD: This study has not collected use of anti-diabetic or anti-hypertensive medications, use of 
statins, or hypercholesterolemia. Blood pressure was measured 3 times using a random zero 
sphygmomanometer after 5 minutes of rest. The average of the last two measurements was 
recorded. 
 
MMKD: This study measured 24h proteinuria. Blood pressure was measured using a 
sphygmomanometer during recruitment of the patient. 
 
NephroTest: Blood pressure was measured 3 times using a standardised automated 
sphygmomanometer (Omron ou Baxter) after 30 minutes of rest. The measurements were 
averaged. 
 
9 
 
RENAAL: This was a clinical trial. Blood pressure was measured 3 times at 1 minute intervals 
using a standard mercury sphygmomanometer after at least 5 minutes of rest. The mean value of 
the 3 readings was recorded for each visit. None of the 3 consecutive DBP readings could have 
differed from the mean by more than 5 mm Hg. If a greater difference occurred, additional 
readings were obtained until 3 consecutive DBP readings met this requirement. 
 
Steno: Although this study has recruited type 1 diabetes mellitus patients with and without 
diabetic nephropathy, only participants with ACR ≥ 30 mg/g at baseline were included in this 
study as a CKD cohort. All participants had hypercholesterolemia. Blood pressure was measured 
2 times with a standard mercury sphygmomanometer or Hawksley random zero 
sphygmomanometer after at least 10 minutes of rest. The two readings were averaged. 
 
Sunnybrook: Blood pressure was measured 6 times using an automated device. The first was 
discarded and the last 5 were averaged. 
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Appendix 3. Acknowledgements and funding for collaborating cohorts 
  
Study List of sponsors 
AASK NIDDK 
ADVANCE National Health and Medical Research Council of Australia program grant 
571281; Servier 
Aichi KAKENHI (09470112, 13470087, 17390185, 18590594, 20590641, 
20790438, 22390133) 
AKDN Canadian Institutes of Health Research; Alberta Innovates - Health 
Solutions; Kidney Foundation of Canada 
ARIC The Atherosclerosis Risk in Communities Study is carried out as a 
collaborative study supported by National Heart, Lung, and Blood Institute 
contracts (HHSN268201100005C, HHSN268201100006C, 
HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, 
HHSN268201100010C, HHSN268201100011C, and 
HHSN268201100012C). The authors thank the staff and participants of the 
ARIC study for their important contributions. 
AusDiab  The Baker IDI Heart and Diabetes Institute, Melbourne, Australia, their 
sponsors, and the National Health and Medical Research Council of 
Australia (NHMRC grant 233200), Amgen Australia, Kidney Health 
Australia and The Royal Prince Alfred Hospital, Sydney, Australia. 
BC Cohort BC Provincial Renal Agency, an Agency of the Provincial Health Services 
Authority in collaboration with University of British Columbia. 
Beaver Dam  NIH/NIDDK DK73217 
NIH/NEI  EY 006594 
Beijing  The research for this study was supported by the Program for New Century 
Excellent Talents in University (BMU2009131) from the Ministry of 
Education of the People’s Republic of China, and the grants for the Early 
Detection and Prevention of Non-communicable Chronic Diseases from the 
International Society of Nephrology Research Committee. 
CARE Alberta Heritage Foundation for Medical Research/Alberta Innovates Health 
Solutions Interdisciplinary Team Grants Program 
CHS The research reported in this article was supported by contracts 
HHSN268201200036C, N01-HC-85239, N01-HC-85079 through N01-HC-
85086, N01-HC-35129, N01 HC-15103, N01 HC-55222, N01-HC-75150, 
N01-HC-45133, and grant HL080295 from the National Heart, Lung, and 
Blood Institute (NHLBI), with additional contribution from the National 
Institute of Neurological Disorders and Stroke (NINDS). Additional support 
was provided through AG-023629, AG-15928, AG-20098, and AG-027058 
from the National Institute on Aging (NIA). A full list of principal CHS 
investigators and institutions can be found at http://www.chs-
nhlbi.org/pi.htm. 
CIRCS N/A 
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COBRA Wellcome Trust, UK 
CRIB  British Renal Society Project Grant Award 
British Heart Foundation Project Grant Award. 
ESTHER Ministry of Research, Science and the Arts Baden-Württemberg (Stuttgart, 
Germany), Federal Ministry of Education and Research (Berlin, Germany), 
Federal Ministry of Family Affairs, Senior Citizens, Women and Youth 
(Berlin, Germany), European Commission FP7 framework programme of 
DG-Research (CHANCES Project). Measurement of urinary albumin was 
funded by Dade-Behring, Marburg, Germany. 
Framingham  NHLBI Framingham Heart Study (N01-HC-25195). 
Geisinger Geisinger Clinic 
GLOMMS-1  Chief Scientist Office CZH/4/656 
Gubbio  Municipal and Health Authorities of Gubbio, Italy; Federico II University, 
Naples, Italy; University of Milan, Milan, Italy; Istituto Superiore di Sanità, 
Rome, Italy; Northwestern University, Chicago, USA; University of 
Salerno, Italy; Merck Sharp & Dohme – Italy. 
HUNT N/A 
IPHS N/A 
KEEP N/A 
KP Hawaii N/A 
KPNW Amgen 
MASTERPLAN The MASTERPLAN study is a clinical trial with trial registration ISRCTN 
registry: 73187232. Sources of funding: The MASTERPLAN Study was 
supported by grants from the Dutch Kidney Foundation (Nierstichting 
Nederland, number PV 01), and the Netherlands Heart Foundation 
(Nederlandse Hartstichting, number 2003 B261). Unrestricted grants were 
provided by Amgen, Genzyme, Pfizer and Sanofi-Aventis. 
MDRD NIDDK UO1 DK35073 and K23 DK67303, K23 DK02904 
MESA This research was supported by contracts N01-HC-95159 through N01-HC-
95169 from the National Heart, Lung, and Blood Institute.  The authors 
thank the other investigators, the staff, and the participants of the MESA 
study for their valuable contributions.  A full list of participating MESA 
investigators and institutions can be found at http://www.mesa-nhlbi.org. 
MMKD The MMKD study was funded by the Austrian Heart Fund and by the 
Innsbruck Medical University. 
MRC Older 
People 
UK Medical Research Council, Department of Health for England, Wales 
and the Scottish Office and Kidney Research UK 
MRFIT The Multiple Risk Factor Intervention Trial was contracted by the National 
Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health 
(NIH), Bethesda, Md.  Follow-up after the end of the trial was supported 
with NIH/NHLBI grants R01-HL-43232 and R01-HL-68140.  The principal 
investigators and senior staff of the clinical centers, coordinating center, 
other support centers and key committees are listed in a previous report 
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(JAMA 1982; 248: 1465-1477). 
NHANES III United States Center for Disease Control 
NephroTest The NephroTest CKD cohort study is supported by grants from: Inserm GIS-
IReSP AO 8113LS TGIR; French Ministry of Health AOM 09114 and AOM 
10245; Inserm AO 8022LS; Agence de la Biomédecine R0 8156LL, AURA, 
and Roche 2009-152-447G. The Nephrotest initiative was also sponsored by 
unrestricted grants from F.Hoffman-La Roche Ltd.  
The authors thank the collaborators and the staff of the NephroTest Study: 
Gauci C, Karras A, Maruani G, Daugas E, d'Auzac C, Jacquot C, Thervet E, 
Roland M, Letavernier E, Boffa JJ, Ronco P, Fessi H, du Halgouet C, 
Vrtovsnik F, Urena P. 
Ohasama Grant-in-Aid(H20-22Junkankitou[Seishuu]-Ippan-009, 013 and H23-
Junkankitou [Senshuu]-Ippan-005) from the Ministry of Health, Labor and 
Welfare, Health and Labor Sciences Research Grants, Japan; Japan 
Atherosclerosis Prevention Fund. 
OKINAWA 83 N/A 
OKINAWA 93 N/A 
Pima This work was supported by the Intramural Research Program of the 
National Institute of Diabetes and Digestive and Kidney Diseases 
PREVEND The PREVEND study is supported by several grants from the Dutch Kidney 
Foundation, and grants from the Dutch Heart Foundation, the Dutch 
Government (NWO), the US National Institutes of Health (NIH) and the 
University Medical Center Groningen, The Netherlands (UMCG). Dade 
Behring, Marburg, Germany supplied equipment and reagents for 
nephelometric measurement of urinary albumin. 
Rancho 
Bernardo  
NIA AG07181 and AG028507 NIDDK DK31801 
REGARDS  This research project is supported by a cooperative agreement U01 
NS041588 from the National Institute of Neurological Disorders and Stroke, 
National Institutes of Health, Department of Health and Human Service. The 
content is solely the responsibility of the authors and does not necessarily 
represent the official views of the National Institute of Neurological 
Disorders and Stroke or the National Institutes of Health. Representatives of 
the funding agency have been involved in the review of the manuscript but 
not directly involved in the collection, management, analysis or 
interpretation of the data. The authors thank the other investigators, the staff, 
and the participants of the REGARDS study for their valuable 
contributions.  A full list of participating REGARDS investigators and 
institutions can be found at http://www.regardsstudy.org 
Additional funding was provided by an investigator-initiated grant-in-aid 
from Amgen.  Representatives from Amgen did not have any role in the 
design and conduct of the study, the collection, management, analysis, and 
interpretation of the data, or the preparation or approval of the manuscript.   
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RENAAL The RENAAL trial was supported by Merck and Company. 
Severance  Seoul city R&BD program (10526), Korea, The National R&D Program for 
Cancer Control, Ministry for Health, Welfare and Family affairs, Republic 
of Korea (1220180), and The National Research Foundation of Korea(NRF) 
grant funded by the Korea government(MEST) (2011-0029348). 
STENO N/A 
Taiwan  This study was supported by Taiwan Department of Health Clinical Trial 
and Research Centre of Excellence (DOH 101-TD-B-111-004) 
ULSAM The Swedish Research Council (2006-6555), the Swedish Heart-Lung 
Foundation, Dalarna University, and Uppsala University. 
ZODIAC N/A 
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